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Abstract
Background: Dissemination of evidence-based practices that can reduce morbidity and mortality is important to
combat the growing opioid overdose crisis in the USA. Research and expert consensus support reducing high-dose
opioid therapy, avoiding risky opioid-benzodiazepine combination therapy, and promoting multi-modal, collaborative
models of pain care. Collaborative care interventions that support primary care providers have been effective in
medication tapering. We developed a patient-centered Primary Care-Integrated Pain Support (PIPS) collaborative
care clinical program based on effective components of previous collaborative care interventions. Implementation
facilitation, a multi-faceted and dynamic strategy involving the provision of interactive problem-solving and
support during implementation of a new program, is used to support key organizational staff throughout PIPS
implementation. The primary aim of this study is to evaluate the effectiveness of the implementation facilitation
strategy for implementing and sustaining PIPS in the Veterans Health Administration (VHA). The secondary aim is
to examine the effect of the program on key patient-level clinical outcomes—transitioning to safer regimens and
enhancing access to complementary and integrative health treatments. The tertiary aim is to determine the
categorical costs and ultimate budget impact of PIPS implementation.
Methods: This multi-site study employs an interrupted time series, hybrid type III design to evaluate the effectiveness of
implementation facilitation for a collaborative care clinical program—PIPS—in primary care clinics in three geographically
diverse VHA health care systems (sites). Participants include pharmacists and allied staff involved in the delivery of clinical
pain management services as well as patients. Eligible patients are prescribed either an outpatient opioid prescription
greater than or equal to 90 mg morphine equivalent daily dose or a combination opioid-benzodiazepine regimen.
They must also have an upcoming appointment in primary care. The Consolidated Framework for Implementation
Research will guide the mixed methods work across the formative evaluation phases and informs the selection of
activities included in implementation facilitation. The RE-AIM framework will be used to assess Reach, Effectiveness,
Adoption, Implementation, and Maintenance of PIPS.
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Discussion: This implementation study will provide important insight into the effectiveness of implementation facilitation
to enhance uptake of a collaborative care program in primary care, which targets unsafe opioid prescribing practices.
Keywords: Opioids, Primary care, Collaborative care, Benzodiazepines, Implementation, Hybrid design, Pharmacist
Evidence supporting the use of opioids for chronic pain is
modest [1, 2], and serious safety, misuse, and abuse con-
cerns have increased over the last two decades [3–7]. In
2017, the opioid overdose epidemic was declared a public
health emergency, and the Council of Economic Advisers
estimated the cost to the USA was $504 billion in 2015
alone [8]. To decrease morbidity and mortality in the con-
text of therapeutic use of opioid therapy for the manage-
ment of pain, a growing body of research and expert
consensus support reducing high-dose opioid therapy,
avoiding opioid-benzodiazepine combination therapy, and
promoting multi-modal pain care in which evidence-based
complementary and integrative health (CIH) treatments are
incorporated alongside pharmacologic treatment [9, 10].
The Veterans Health Administration (VHA) launched
the Opioid Safety Initiative (OSI) in early 2013 as part of
a larger strategy to respond to the opioid epidemic. The
OSI’s objectives include engaging patients in discussions
about safer medication treatment regimens. While there
has been some success in decreasing the number of pa-
tients prescribed risky opioid regimens [11], meeting the
challenge of de-implementing high-risk medication regi-
mens using patient-centered methods is still a major
concern across the VHA [12].
To address the needs of clinicians at VHA facilities, we
designed a collaborative care clinical program, known as
Primary Care-Integrated Pain Support (PIPS). The intent of
PIPS is to decrease the proportion of patients on high-risk
opioid regimens for chronic pain and increase the propor-
tion of patients treated with CIH treatments, all while pre-
serving or improving quality of life and functional status.
PIPS was based on a successful model of a pharmacist-led
collaborative care intervention in VHA [13], qualitative
work that identified the need for improved coordination of
pain care and communication among providers [14], and
review of similar evidence-based interventions that aimed
to decrease benzodiazepine use [15] or decrease opioid use
[16]. Specific components of the intervention include letters
inviting patients to ask providers about PIPS, primary care
provider education about PIPS, a PIPS referral template for
primary care providers, and a structured program in which
clinical pharmacists work one-on-one with patients to tran-
sition them to safer regimens and increase access to CIH
treatments. Clinical pharmacists are key PIPS providers,
working closely with primary care teams to taper medica-
tions and motivate and refer patients to CIH treatments.
Collaborative care models, where non-physicians
provide support and care coordination to high-need
patients, have consistently shown benefit in chronic pain
studies, particularly in the VHA [17–19]. However, these
models are not typically well-integrated into regular clin-
ical practice without concerted implementation support.
Implementation facilitation has been used successfully to
increase the uptake of evidence-based practices and pro-
grams (EBPPs) in primary care and other clinical settings
[20]. It is a multi-faceted strategy that focuses on sup-
porting individuals and groups in adapting EBPPs for
their setting and problem-solving around implementa-
tion barriers. As part of implementation facilitation,
external and internal facilitators work together to sup-
port implementation through various discrete imple-
mentation activities [21]. The remainder of this section
will focus on describing the details of the PIPS clinical
practice as well as the implementation strategy, followed
by a description of the aims of this study.
Clinical practice
Patients eligible for PIPS have (1) an upcoming primary
care appointment within 2–4 weeks at one of the three
sites and (2) active opioid prescriptions at any VHA facil-
ity totaling 90 mg morphine equivalent daily dose
(MEDD) or more or active, concurrent opioid and benzo-
diazepine prescriptions. Initiation of PIPS engagement
with these patients is as follows:
1. Local clinic staff mail a letter to eligible patients
2–4 weeks in advance of a routine primary care
appointment. The letter explains that there are
safety concerns around opioid prescriptions and
that PIPS may help the patient reduce
medication use and engage in CIH treatments.
Patients are encouraged to bring the letter with
them to their upcoming primary care
appointment to discuss with their providers.
2. During the appointment, the primary care provider
discusses medication safety concerns and the
rationale for CIH treatments and if the patient
agrees, refers them to PIPS via a templated
pharmacy PIPS consult. Providers may also refer
eligible patients who have not received a letter (e.g.,
incorrect mailing address).
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3. For PIPS-referred patients, a medical assistant
schedules an intake appointment for the patient
with the clinical pharmacist. The objectives of the
first appointment are to build rapport, review the
patient’s preferences for CIH treatment, initiate the
taper plan if the patient agrees, and set a schedule
for follow-up. The clinical pharmacist uses a guide-
line for dose tapering that specifies dose and num-
ber of pills supplied at each 2-week interval but can
vary from the guideline as dictated by clinical
circumstances. If a dose reduction is planned, but
the patient is unwilling, the clinical pharmacist uses
clinical judgment to alter the schedule for PIPS
follow-up, as needed.
4. The clinical pharmacist follows up with the patient
based on patient needs. Follow-up sessions may be
conducted by telephone or in-person depending on
the patient’s preference and clinical course. The
topics covered include progress with medication
changes, quality of life and pain-related functional
interference, patient safety, and engagement in CIH
treatments. In addition to overseeing patients’
tapering progress, the clinical pharmacist places
referrals for patients’ preferred CIH treatments,
tracks patients’ attendance, and addresses any
barriers to CIH treatment engagement. Primary
care providers are tagged to clinical pharmacist
notes, so they are made aware of the progress of
tapers and expected date of patients’ discharge from
PIPS. A standardized note template is used at each
site to consistently track patient progress over time.
Patients may stay enrolled in PIPS for up to
6 months based on their needs.
Implementation strategy
We will use an implementation facilitation strategy [20] to
enhance uptake and sustainability of PIPS. An external
facilitation (EF) team, consisting of clinical and implemen-
tation experts, will work with an internal facilitation (IF)
team at each site, consisting of an internal facilitator and
local champion. The EF team includes a physician and
two clinical psychologists with expertise in implementa-
tion. The physician is an expert in PIPS delivery and will
serve as the primary external facilitator, whereas the two
psychologists will consult with the EF and IF team as
needed. The internal facilitator within the IF team is an
experienced physician familiar with the facility’s proce-
dures, organizational structures, clinical processes, and
culture. The local champion within the IF team is a clin-
ical pharmacist who provides formal marketing, including
emails or presentations and directly interfaces with pri-
mary care physicians. The EF and the IF team will meet at
least twice per month by phone and communicate as
needed in between regular meetings.
In addition, we will use a case-finding dashboard [22]
to identify PIPS-eligible patients across the three sites.
Local site staff will use the dashboard bi-weekly to view
lists of patients and generate letters for mailing to
patients with upcoming primary care appointments.
Table 1 provides a description of each of the implemen-
tation facilitation activities being applied to PIPS imple-
mentation; these activities were drawn from existing
literature [22].
Aims
The overarching objective of this study, following an
implementation-effectiveness hybrid type III design [23],
is to understand how to facilitate uptake of the PIPS clin-
ical practice. The primary aim is to determine if imple-
mentation facilitation leads to uptake and sustained use of
PIPS and which activities within implementation facilita-
tion are the active components leading to successful
implementation. The secondary aim is to examine the
effectiveness of PIPS on clinical outcomes, including tran-
sitions to safer medication regimens and uptake of CIH
treatments. The tertiary aim will determine the budget im-
pact of implementation of PIPS, which will provide VHA
leadership with a cost estimate to inform decisions about
future spread of PIPS [24]. The three major time periods
or phases are (1) an 18-month pre-implementation period,
(2) an 18-month implementation period, and (3) a
6-month sustainment period.
Methods
In this section, the study sites will be described, followed
by the evaluation framework, study participants, mea-
sures, data collection, and analysis plans for each study
aim. The study protocol was approved by the institu-
tional review boards at the site of the principal investiga-
tor (VA Connecticut Healthcare System) and at the PIPS
implementation sites. A waiver of informed consent for
patients and providers was approved, as the PIPS clinical
program was deemed not human subjects research.
Study sites
The PIPS clinical program and accompanying imple-
mentation facilitation strategy is being employed and
evaluated at three VHA health care systems: VA East-
ern Colorado Health Care System (ECHCS), Central
Arkansas Veterans Healthcare System (CAVHS), and
Tennessee Valley Healthcare System (TVHS). At the
VA ECHCS, the main facility and two affiliated out-
patient clinics are included in PIPS implementation.
At the CAVHS, the two main facilities and eight affil-
iated outpatient clinics are included in PIPS imple-
mentation. At the TVHS, the two main facilities and
two affiliated outpatient clinics are included in PIPS
implementation. Multiple primary care clinics are
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Table 1 Implementation facilitation activities
Activity Definition
Engagement with the facilitation team The IF and EF teams engage during monthly project-wide and separate site-specific
team calls. The IF team also contacts the EF team whenever questions arise related
to PIPS implementation, while the EF team engages the IF team outside of scheduled
calls when the need arises.
Academic detailing/education Educating providers and key stakeholders about PIPS or other pain management
assessment and treatment tools. This strategy involves direct outreach by the IF
team and sometimes the EF team to educate providers at a given site. The intent is
to promote providers’ use of PIPS through clear and regular education about the
program and pain management strategies, including CIH treatments. This strategy
can include one-on-one interactions with providers about PIPS treatment, PIPS
educational meetings with different stakeholder groups (e.g., providers, administrator,
veteran patient/consumer group, family stakeholders), assessment of PIPS knowledge
and motivation to enroll patients in PIPS, and providing positive feedback for improved
clinical practices as they relate to PIPS objectives.
Problem-solving This activity is based on ongoing assessment, either formal (interviews, surveys) or informal
(conversations), of implementation barriers to PIPS implementation. This information is
used to troubleshoot challenges as they arise, using regularly scheduled site-specific and
project-wide calls or communication in between meetings as necessary.
Audit and feedback This activity is conducted monthly unless another schedule is deemed necessary. In brief,
it involves collecting and summarizing clinical performance data related to PIPS (e.g., number
referred, enrolled, completed) and providing that feedback to the IF and local champion at
the site. This activity allows the implementation team to review progress and adjust behavior
as necessary to enhance enrollment.
Capturing and sharing local knowledge This activity occurs on the project-wide calls, but may also occur through informal
communication (e.g., email). This activity is meant to help sites capture and share what
is working to facilitate PIPS implementation in their clinical setting.
Changing record systems Altering record systems as needed for PIPS implementation. The main records for PIPS are
the letter to patients (explaining PIPS), a consult template for referral to PIPS, and intake
and progress note templates stored in the electronic medical record. Each site can modify
these records to fit their culture and care processes.
Marketing and distribution of materials This activity typically involves the use of flyers and announcements in meetings or via email.
It may occasionally overlap with academic detailing in that some marketing materials will be
educational, describing key PIPS components and potential benefits to patients and providers.
Changing the clinical teams This activity involves altering the team that provides care to PIPS patients, whether that be
through replacing providers, adding new members, or changing duties and responsibilities.
For example, if a new clinical pharmacist is brought into the team to help with referrals to
PIPS, then that would represent a change in the clinical team.
Changing the implementation team Changing or adding an IF, EF, or local champion to the implementation team.
Developing materials and adding
them to a shared library
Placing PIPS-related materials in a shared library (computer-based or other) for the purposes
of making it easier to access items and information that could be used to teach clinical team
members or other stakeholders about PIPS and for providers to deliver the program.
Informing local opinion leaders Members of the implementation team reach out to providers or administrators at a site who
are educationally influential to inform them about PIPS and encourage them to support PIPS
implementation (e.g., by mentioning PIPS at a staff meeting or talking about the benefits of
PIPS for their patients).
Engaging national and regional
policy makers
This activity entails the EF or IF teams reaching out to national or regional leadership about PIPS,
informing them about implementation progress, or soliciting feedback on potential modifications.
Providing technical assistance
and coaching
This activity is intended to help the IF teams and local staff deliver a high-quality PIPS clinical
program. It can include providing assistance on the use of the automated case-finding dashboard
tool or consult template or helping the provider improve their PIPS-related skills (e.g., adjusting
medication tapering protocols, providing recommendations for CIH treatments).
Participation in a community of
practice (COP)
The COP meeting occurs monthly for IF team members and providers and is led by the clinical
expert of the EF team. Given the challenges and skills required to work with patients on opioid
tapering and motivating them to engage with CIH treatments, the purpose of the COP is to
advance accurate knowledge, improved skills, and positive attitudes when working with patients
in the PIPS program.
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located within the main facilities and outpatient
clinics. The sites all have strong clinical expertise in
opioid safety but vary in the degree to which
multi-modal pain care and opioid safety initiatives
have penetrated primary care practice.
Aim 1: Implementation evaluation
Implementation will be assessed in two ways: (1)
mixed methods formative evaluation during the pre
-implementation, implementation, and sustainment
phases to monitor our approach to implementation
facilitation and progress [25] and (2) fidelity to imple-
mentation facilitation activities.
Each phase of formative evaluation has different ob-
jectives. During the 18-month pre-implementation
phase, we will identify barriers and facilitators prior to
implementation. During the 18-month implementation
phase, implementation progress will be monitored and
implementation activities modified as needed. During
the 6-month sustainment phase, we will gather data
related to successes or failures after implementation,
including stakeholders’ perceptions of the utility of
PIPS, satisfaction with the implementation process, and
recommendation for future implementation refine-
ments. The implementation facilitation fidelity assess-
ment will allow us to determine the degree to which
certain implementation facilitation activities (Table 1)
were used during the implementation period and how
they relate to the uptake of PIPS.
Evaluation framework
The study relies on two complementary implementation
frameworks—the RE-AIM framework [26, 27] and the
Consolidated Framework for Implementation Research
(CFIR) [28]. Four dimensions within RE-AIM will be
used to assess implementation—Reach, Adoption, Imple-
mentation, and Maintenance (with the Effectiveness
domain being applicable to the secondary aim of this
study).
Reach refers to the proportion of patients touched by
PIPS. Adoption refers to the proportion of providers
who use PIPS. Implementation refers to adaptations
made to improve uptake of the clinical practice as well
as fidelity to the PIPS protocol. Maintenance refers to
whether PIPS is maintained over time and will be
assessed during the 6-month, sustainment period.
The CFIR is a meta-theoretical framework that
includes five domains and 39 constructs that influence
the implementation of EBPPs. The CFIR was selected to
guide the mixed methods formative evaluation to iden-
tify facilitators and barriers to implementation as well as
the chosen implementation facilitation activities. Since
not all 39 constructs were relevant to the clinical
practice we are implementing, we selected the CFIR
constructs per domain most relevant to PIPS implemen-
tation and tied them to the previously outlined specific
implementation facilitation activities (see Table 2).
Mapping of CFIR to implementation facilitation activities
The intervention characteristics domain refers to attri-
butes of interventions that influence successful imple-
mentation. Within this domain, there are five key
constructs that could affect PIPS implementation, ran-
ging from evidence strength and quality to cost. Facilita-
tion activities that can be used to address these issues
include engagement with the facilitation team and
academic detailing.
The inner setting domain refers to features within the
local context that can influence the PIPS implementation.
Three key constructs—networks and communication, cul-
ture, and implementation climate—are important matters
for PIPS implementation. For example, to enhance com-
patibility, we will capture and share local knowledge
among leadership and providers and engage in problem
-solving as issues arise.
The impact of the outer setting domain may be medi-
ated through the inner setting, but certain economic,
social, and political characteristics may impact imple-
mentation success. For this implementation work, we
are interested in two key constructs: patient needs/re-
sources and external policy/incentives. For example, to
target patient needs and resources, we use a community
of practice to troubleshoot potential barriers to patients
receiving care.
The role of individuals in implementation success can-
not be underestimated. For PIPS implementation, indi-
viduals’ knowledge and beliefs about interventions is
most relevant. To address this construct, providers
receive academic detailing and materials are developed
for sharing among key staff.
Within the process domain, we are primarily inter-
ested in engaging key opinion leaders and making sure
all appropriate personnel receive education and training
related to PIPS.
Study participants
Participants include stakeholders at each facility engaged
in pain management, including clinicians (e.g., pharma-




Data for the Reach, Adoption, and Maintenance dimen-
sions will be obtained from VHA administrative data
pulled directly from the electronic medical record (i.e.,
consults, clinical notes for enrolled PIPS patients) across
the relevant implementation or sustainment periods.
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Staff interviews
The CFIR informs the development of all semi-structured
interview guides. Interviews will be over the phone but
may occur in person during a site visit and are used across
all phases of formative evaluation (pre-implementation,
implementation, and sustainment phases) to obtain infor-
mation about factors that might support or hinder PIPS
implementation and to inform the use of implementation
facilitation. Interviews will be audio-recorded and
transcribed verbatim using VA’s centralized transcription
service program.
Organizational change measure
We will assess organizational readiness using the
Organizational Readiness for Implementing Change
(ORIC) instrument [29]. The ORIC is a reliable and
valid ten-item survey measure for assessing the shared
belief among members of an organization that their
organization is ready for change. It has two subscales:
change commitment (resolve to implement a change)
and change efficacy (collective capability to implement
a change). Each item is rated using a five-point ordinal
scale, ranging from “disagree” to “agree.” The total
score ranges from 10 to 50, with higher scores indica-
tive of greater organizational readiness for change.
Implementation facilitation training and fidelity
Two implementation facilitation experts (clinical psychol-
ogists with implementation facilitation training) will pro-
vide training to the EF and the IF teams to enhance
fidelity to implementation and ensure implementation
facilitation activities are recorded for fidelity monitoring.
The training will include (1) descriptions of the imple-
mentation facilitation activities, (2) examples of these
activities in the context of PIPS, and (3) how to record
these activities in a monthly log. The EF and IF team
members will receive either group or one-on-one training
on a call by at least one of the implementation facilitation
experts prior to the start of implementation. Training will
be delivered in person whenever possible, but may also be
delivered by phone when an in-person visit is not feasible.
The training materials include a 60-min slideshow presen-
tation and three sample vignettes that illustrate implemen-
tation facilitation activities (see Additional file 1). The
presentation describes each of the implementation facilita-
tion activities and provides examples relevant to PIPS
Table 2 CFIR domains, constructs, and implementation facilitation activities
CFIR domain CFIR constructs Implementation facilitation activities
Intervention characteristics -Evidence strength and quality -Engagement with facilitation team
-Relative advantage -Academic detailing
-Adaptability -Audit and feedback
-Design quality and packaging -Change clinical team
-Cost -Develop and share materials
-Inform local opinion leaders
Inner setting -Networks and communication -Academic detailing
-Culture -Problem-solving
-Implementation climate -Audit and feedback
-Tension for change -Capture and share local knowledge
-Compatibility -Change record systems
-Marketing and distribution of materials
-Change implementation team
-Provide technical assistance and coaching
Outer setting -Patient needs and resources -Engagement with facilitation team
-External policy and incentives -Engaging national and regional policy makers
-Community of practice
Characteristics of individuals -Knowledge and beliefs about the intervention -Engagement with facilitation team
-Academic detailing
-Develop and share materials
-Inform local opinion leaders
Process -Engaging -Academic detailing
-Marketing and distribution of materials
-Inform local opinion leaders
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implementation. The sample vignettes describe fictitious
PIPS implementation efforts intended to promote under-
standing and accuracy when identifying and recording
implementation activities. The expert trainer(s) will review
each vignette one at a time and ask trainees to identify
which implementation facilitation activities are occurring
in the given vignette, addressing any questions when they
arise. For the last portion of the training, the trainees will
be instructed on how to complete a monthly online imple-
mentation facilitation strategy log for recording all facilita-
tion activities. After the training, each IF team member
will be asked to independently review eight additional
vignettes for the presence or absence of implementation
facilitation activities and return them to the trainers
within 1 week of training. The expert trainers will review
each of the trainee’s responses and provide feedback or
additional training if warranted.
During the PIPS implementation phase, the EF and IF
team members will complete a 10- to 15-min facilitation
log each month, distributed via REDCap (a secure web
application). The items include questions about the fre-
quency of engagement in, and duration of, the various
implementation facilitation activities and free-text fields
for elaboration on these activities (see Additional file 2).
The monthly assessment will allow us to directly
measure how certain facilitation activities influence PIPS
implementation over time.
Data analysis
Reach is determined by tracking the number and pro-
portion of eligible patients at the site during implemen-
tation who enrolled in PIPS monthly (i.e., number of
patients enrolled in PIPS divided by eligible patients).
Adoption by a provider is defined as the referral of one
or more patients to PIPS. To calculate provider adop-
tion, the case-finding dashboard archives all primary
care providers who have an eligible patient at the site
during the implementation period. We will then divide
the number of providers who made at least one referral
by the total number of providers, again relying on VHA
administrative data. Measuring Maintenance involves
tracking the proportion of eligible patients referred to
PIPS monthly, comparing implementation and sustain-
ment time-periods using VHA administrative data.
Staff interviews
Grounded theory methodology will be used for the
qualitative analysis of interview transcripts [30, 31]. Spe-
cifically, open coding will be conducted initially, identify-
ing key concepts that emerge from the participants’
language. Descriptive phrases (codes) will be assigned to
segments of text, relying on qualitative analysis software
to facilitate coding and sorting of data. Similarities and
differences in themes will be examined by coders as part
of a constant comparisons analysis. These themes will be
discussed with the research team and refined through
discussion.
Fidelity
The ability of the raters to correctly identify the
absence/presence of specific implementation facilitation
activities is tested using seven vignettes. Following each
vignette, raters will be asked to identify which, if any, of
fourteen implementation facilitation activities are uti-
lized. Ratings will be calculated for the appraisal of each
implementation facilitation activity across the vignettes.
The established gold standard is the study leadership’s
inclusion/exclusion of an implementation facilitation
activity in a given vignette. The denominator used for
each calculation will be based upon the number of raters
by the number of vignettes total (total = 80). Sensitivity
and specificity will be calculated to determine partici-
pants’ ability to accurately identify the activities
described in the vignettes. For scores not in acceptable
ranges (< .75), additional training will be conducted.
Aim 2: Effectiveness evaluation
Effectiveness refers to the degree to which PIPS meets
clinical goals. The clinical goals of PIPS are to transition
patients to safer medication regimens and to expand
uptake of CIH treatments. We define the transition to a
safer medication regimen as the reduction of opioid dose
from greater than or equal to 90 mg MEDD to less than
90 mg MEDD, or as the transition from combination
opioid-benzodiazepine receipt to only one or the other
(i.e., discontinuation of one medication class) without a
dose increase in the other. The uptake of a CIH treat-
ment is defined as receipt of a CIH treatment appoint-
ment. CIH treatments include rehabilitation medicine as
well as complementary and integrative medicine treat-
ments (e.g., acupuncture).
Study participants
Patient eligibility criteria for a monthly cohort are (1) hav-
ing an active opioid prescription greater than or equal to
90 mg MEDD for the treatment of chronic non-cancer
pain OR concurrent opioid and benzodiazepine prescrip-
tions (regardless of dose) and (2) having a routine primary
care provider visit coming up within a month.
Data collection
Data will be obtained from the VHA’s administrative
data, relying on outpatient visit and prescription data
sources. Identification of CIH treatments will be based
on previous administrative data-based work [32].
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Data analysis
We will assess the effectiveness of PIPS in safely achieving
its clinical targets using an interrupted time series (ITS)
design with three study periods (18 months of pre-facilita-
tion, with 18 months of facilitation, and 6 months of sus-
tainment) divided into monthly time cohorts. Veterans
will be assigned to the time cohort representing the
month in which they met eligibility criteria for PIPS and
will be followed prospectively to observe whether they
transition to safer medication regimens or utilize CIH
treatments. Monthly rates will be assessed, using mixed
effects logistic regression models that will incorporate
indicators for the study period, variables capturing time
elapsed since the beginning of each study period, site ran-
dom effects, and patient characteristics. Control sites will
be selected for the three PIPS sites based on similarity in
prevalence of high-dose opioid patients, prevalence of
sedative co-prescribing, and facility size. Outcomes for
patients at control sites will be included in the models and
designated by a control site indicator to help protect
against confounding from secular trends and system-wide
effects (e.g., policy changes). Coefficients estimated for the
study period indicators will indicate the immediate
changes in outcomes upon entering the PIPS facilitation
period and the sustainment period, in comparison to the
pre-facilitation period. The coefficients estimated for the
time elapsed since the beginning of each study period will
represent how PIPS facilitation impacted trends in out-
comes over time in each of the three study periods.
We hypothesize significant increases in slopes in the
facilitation period, compared to the pre-facilitation
period, for the proportion of patients transitioning to
safer opioid regimens and for the proportion of patients
utilizing CIH treatments over time. We hypothesize that
there will not be significant level changes in these out-
comes at the onset of the PIPS facilitation period. We
are unsure if there will be sufficient power to detect sig-
nificant changes in slope or level in the maintenance
period. If there is sufficient power, we would expect sig-
nificant increases in outcome slopes in the maintenance
period compared to the pre-facilitation period, but the
magnitude of these changes would be smaller than those
in the comparison of slopes in the facilitation vs.
pre-facilitation periods. We hypothesize that significant
level changes will not be present at the onset of the
maintenance period compared to the facilitation period.
Our use of the ITS design and analytic strategy is in line
with recommended best practices [33, 34]. The interven-
tion will occur independently of other changes over time
and is unlikely to affect data collection, as the data come
from administrative data. The primary outcomes will be
measured objectively (i.e., administrative data), covering
100% of the final sample at each time point. We prespeci-
fied the shape of the intervention effect and have
described our sample calculations size in the power ana-
lysis section. We will be using time series regression
models, accounting for and considering potential meth-
odological issues associated with time series analyses (e.g.,
auto-correlation, time-varying confounders).
Power analysis
Based on the prevalence of eligible patients at the three
sites, we expect approximately 150 patients to be eligible
per site per month. We estimated the proportion of
patients who change their opioid medication to a safer
regiment without influence from PIPS to be 20% in the
pre-facilitation period. Assuming a doubling of the
patients moving to safer regimens during the pre-facili-
tation period to 40% within the PIPS facilitation and
maintenance periods, setting alpha = .05, with a
two-tailed test, we will have sufficient power (> 90%) to
detect an odds ratio (without comparison sites) of 2.08
(95% CI 1.16, 3.75) with 130 patients per group (to allow
for 20% attrition). There is no existing research from
which to evaluate this effect size. However, given the
expected wide range of readiness to adopt this clinical
program, we anticipate this effect size is reasonable and
clinically meaningful.
Aim 3: Economic evaluation
A budget impact analysis will examine three categories
of costs: (1) implementation, (2) PIPS clinical program,
and (3) consequent costs. Implementation costs include
staff, length of meeting time participation, and supplies.
Clinical program costs include the time of the pharma-
cists who develop and manage dose tapering protocols,
the letter mailing cost, and the extra time for the pri-
mary care provider to introduce PIPS and encourage
other CIH treatments. Consequent cost represents the
change in healthcare utilization costs from pre-PIPS to
post-PIPS periods. Both implementation and clinical
program costs will be measured through the micro-cost-
ing method [35], using an approach that is similar to a
previous cost analysis of an implementation project in
the VHA [36].
Study participants
Participants include patients described in the “Aim 2:
Effectiveness evaluation” section as well as the pharma-
cists and primary care providers.
Data collection
Data will be obtained from the VHA’s administrative
data and logs kept by study personnel. The logs will
include information about the total staff FTE (full-time
equivalent), length of meeting time, and number of par-
ticipants by title of employment, relying on the VHA
employment pay category and the average salary in each
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employment category to estimate cost. The logs will also
include a list of supplies needed to implement PIPS, in-
cluding equipment and materials (e.g., guides, instruc-
tions) as well as an “Other” category to document
unexpected expenses.
Data analysis
To ascertain consequent cost, an ITS model like those
described above for assessing PIPS clinical targets will be
used to evaluate changes in healthcare utilization associ-
ated with the implementation of PIPS. Primarily, this
design will compare post-PIPS (in the facilitation and sus-
tainment periods) outcomes and trends to pre-PIPS levels
within the three intervention sites; however, sensitivity
analyses will be conducted to compare PIPS sites to
closely matched control sites to guard against confusing
PIPS effects with secular trends of disruptions affecting all
sites in the health care system. We will account for vary-
ing lengths of the study periods of interest, separate types
of healthcare utilization (pain management related care
vs. care for other medical conditions), and regional vari-
ation in healthcare utilization in our model.
Project status
As of August 2018 (manuscript submission), PIPS is
in the implementation phase, with two VA health care
systems (sites) in the implementation phase since
March 2017. A third VA health care system began
the 18-month implementation phase in May 2018.
The project team had difficulty identifying a third
site, and the internal facilitator changed during the
pre-implementation period at the third site. Pre-im-
plementation formative evaluation was completed at
all sites, and implementation/progress-focused forma-
tive evaluation was beginning at two sites. In both
sites that began implementation in 2017, at least 91
patients have enrolled, with 3 patients enrolled at the
site that began in 2018.
Discussion
To address the growing opioid epidemic, it is important
to understand optimal strategies for implementing evi-
dence-based practices in primary care settings. As part
of this hybrid, type III trial, we are evaluating the
effectiveness of the implementation facilitation ap-
proach, which has been used previously to implement
evidence-based practices in primary care [20]. The
current trial will not only identify which activities within
implementation facilitation are key to implementation of
a collaborative care clinical program based in primary
care (PIPS) but also evaluate the effectiveness of PIPS on
key clinical outcomes. Quantitative and qualitative data
collected as part of the stages of the formative evaluation
will contribute to a more in-depth understanding of
which factors are facilitating or limiting successful
implementation. The ITS design will allow us to see how
sites performed with respect to clinical outcomes before,
during, and after the application of implementation fa-
cilitation. The findings from this study will inform
spread of PIPS beyond the initial three health care sys-
tems, as well as the implementation of similar collabora-
tive care, primary-care-based clinical programs.
In addition to enhancing the literature examining the
effectiveness of implementation facilitation, including
the integration of CFIR and implementation facilitation,
the study also adds to fidelity measurement literature
through the facilitation fidelity measurement.
Limitations
There are some limitations that should be noted. First, the
VHA has several initiatives that target opioid safety [11],
including interventions focused on primary care, which
will likely overlap with the study period. It is not possible
to separate the impact of those initiatives from the impact
of PIPS on clinical care. Moreover, clinical leadership and
staff will have to respond to and continue to address VHA
initiatives during the study period which may impact the
ability of staff at our study locations to focus on PIPS
implementation. Second, PIPS is being implemented in
VHA and may not generalize to other healthcare systems,
especially those that do not have clinical pharmacists inte-
grated into primary care practice.
Conclusion
There is growing recognition that the field of implementa-
tion science offers important guidance to increase the likeli-
hood of success of care-delivery innovations such as PIPS,
through identification of key factors influencing their adop-
tion [37]. This study has the potential to (1) provide the
field with an effective way in which to implement a collab-
orative care program designed to improve the safety and
quality of pain treatment among veterans, (2) inform the
spread of other collaborative care clinical programs, and (3)
advance the use of implementation facilitation.
Additional files
Additional file 1: Sample Vignette. (DOCX 12 kb)
Additional file 2: PIPS monthly facilitation log. (PDF 70 kb)
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